公开(公告)号：US10316361B2

公开(公告)日：2019-06-11

申请号：US14232981

申请日：2012-07-16

申请人： Saraswati V. Sukumar ,  Christopher Benedict Umbricht ,  Antonio C. Wolff ,  Mary Jo Steele Fackler ,  Zhe Zhang ,  Leslie M. Cope ,  Kala Visvanathan ,  Peng Huang

发明人： Saraswati V. Sukumar ,  Christopher Benedict Umbricht ,  Antonio C. Wolff ,  Mary Jo Steele Fackler ,  Zhe Zhang ,  Leslie M. Cope ,  Kala Visvanathan ,  Peng Huang

IPC分类号： C12P19/34 ,  C12Q1/68 ,  C12Q1/6874 ,  C12Q1/6886

摘要： To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.

公开(公告)号：US20140221242A1

公开(公告)日：2014-08-07

申请号：US14232981

申请日：2012-07-16

申请人： Saraswati V. Sukumar ,  Christopher Benedict Umbricht ,  Antonio C. Wolff ,  Mary Jo Steele Fackler ,  Zhe Zhang ,  Leslie M. Cope ,  Kala Visvanathan ,  Peng Huang

发明人： Saraswati V. Sukumar ,  Christopher Benedict Umbricht ,  Antonio C. Wolff ,  Mary Jo Steele Fackler ,  Zhe Zhang ,  Leslie M. Cope ,  Kala Visvanathan ,  Peng Huang

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6874 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154

摘要： To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.

摘要翻译： 为了更好地了解激素受体阳性和阴性乳腺癌的生物学，并确定疾病进展的甲基化基因标记，使用Illumina Infinium HumanMethylation27阵列对103例原发性浸润性乳腺癌和21例正常乳腺样品进行全基因组甲基化阵列分析 查询了27,578个CpG位点。 40个CpG基因座显示ER-阳性或ER阴性肿瘤特异性差异甲基化。 40个ER亚型特异性基因座中的每一个都使用“癌症基因组图谱”（TCGA）中独立的，公开的甲基化数据集进行了计算机验证。 此外，确定了与疾病进展显着相关的100个甲基化CpG基因座。 提供了含有ER亚型特异性基因座的阵列及其在乳腺癌诊断和治疗方法中的应用。